Latest news with #HiFiWGS
Yahoo
13-05-2025
- Business
- Yahoo
PACB Stock May Rise Following the Deal With Chulalongkorn University
PacBio PACB recently announced a strategic collaboration with Chulalongkorn University, one of Thailand's foremost institutions in genomic and translational research, to implement PacBio's HiFi whole genome sequencing (WGS) as part of the newborn screening research program. This initiative marks the first population-scale deployment of PacBio's HiFi technology in the Asia Pacific region. It is designed to evaluate how comprehensive genomic data can enable earlier and more accurate identification of rare, treatable conditions in newborns. By integrating PacBio's advanced long-read sequencing capabilities, the program will help uncover a broader spectrum of genetic variants that often go undetected with traditional screening methods. Through this effort, PacBio and Chulalongkorn University aim to build a scalable model that could transform early-stage diagnostics and public health planning on a global scale. Following the announcement, shares of the company closed flat at $1.12 on Friday. In the year-to-date period, PACB's shares have lost 38.8% compared with the industry's 10.1% decline. The S&P 500 decreased 4.4% in the same time frame. This collaboration positions PacBio at the forefront of a major shift in global healthcare, signaling growing adoption of its HiFi sequencing technology for large-scale clinical applications. By demonstrating real-world utility in a critical use case, such as newborn screening, PacBio not only expands its footprint in the fast-growing Asia Pacific region but also builds a compelling case for broader international adoption. Successful implementation could lead to long-term revenue growth from government contracts, public health partnerships, and increased demand for HiFi systems, reinforcing investors' confidence in the scalability and relevance of PacBio's platform in precision medicine. Meanwhile, PACB currently has a market capitalization of $336.1 million. The company expects its earnings to grow 13.1% in 2025. Image Source: Zacks Investment Research The collaboration between PacBio and Chulalongkorn University is a landmark initiative that highlights the transformative potential of WGS in public health. Traditional newborn screening programs typically rely on targeted panels to detect a limited number of conditions, often missing rare or complex genetic disorders. PacBio's HiFi WGS, by contrast, delivers highly accurate, long-read genomic data that captures regions of the genome inaccessible to short-read technologies. This includes structural variants, repeat expansions, and epigenomic information, all of which are critical for identifying a wider spectrum of genetic risks from birth. By enabling a more complete and precise view of the newborn genome, the technology opens the door to earlier diagnosis and intervention for conditions that might otherwise remain undetected until much later in life. Chulalongkorn University, through its Center of Excellence for Medical Genomics, is likely to bring deep expertise and infrastructure to the table, making it an ideal partner for this endeavor. The university aims to build a robust and scalable research model that can be replicated across other national health systems. This research-driven approach not only enhances clinical care but also contributes to public health data systems, laying the groundwork for informed policy decisions, better resource allocation, and eventually, personalized healthcare strategies on a national scale. On a broader level, this initiative positions Thailand as a leader in precision medicine within the Asia Pacific region and places PacBio at the center of a growing global movement toward genome-informed healthcare. By successfully deploying HiFi WGS in a population-scale screening program, PacBio is setting a benchmark for how advanced sequencing technologies can be integrated into public health. This could catalyze similar initiatives in other countries, unlocking new markets and reinforcing PacBio's reputation as a pioneer in genomic innovation. With increasing recognition of genomics as a foundational tool in early disease detection and prevention, this collaboration not only accelerates scientific progress but also enhances PacBio's long-term commercial and strategic outlook. Per a report by Grand View Research, the global whole genome sequencing market size was estimated at $2.12 billion in 2024 and is expected to witness a CAGR of 22.17% from 2025 to 2030. The WGS market is experiencing significant growth, driven by a confluence of technological advancements, decreasing costs, and a growing demand for personalized medicine. Several key factors contribute to this expansion, transforming the landscape of genomics and impacting various sectors, including healthcare, research, and agriculture. PACB carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and Boston Scientific Corporation BSX. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted EPS of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. CVS Health has a long-term estimated growth rate of 11.4%. CVS's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 13.3%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-05-2025
- Health
- Yahoo
First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand
Collaboration leverages HiFi's unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening MENLO PARK, Calif. and BANGKOK, May 05, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB) a leading provider of high-quality, highly accurate sequencing platforms, and Chulalongkorn University, a national leader in genomic and translational research, today announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as part of a newborn screening research program. This marks the first initiative in Asia Pacific to explore the use of PacBio's HiFi sequencing technology at population scale - an effort designed to evaluate how comprehensive genomic data can support earlier, more accurate identification of rare and treatable conditions in newborns. The collaboration highlights Thailand's growing leadership in precision medicine and offers a potential model for countries seeking to modernize newborn screening with genome-wide approaches. 'Our shared goal is to establish a robust and scalable research model for genomic newborn screening that helps uncover the genetic basis of undiagnosed conditions from birth,' said Professor Vorasuk Shotelersuk from the Center of Excellence for Medical Genomics, Chulalongkorn University, Thailand. 'We are excited to work with PacBio to bring this vision closer to reality for families in Thailand.' Traditional newborn screening programs have relied on targeted panels that detect a limited subset of conditions based on specific molecular pathologies. Recent advances in genome sequencing now make it possible to take a broader, more comprehensive approach, starting at birth. PacBio's HiFi WGS leverages long-read technology to generate highly accurate, complete genomic data, including regions that are typically inaccessible to short-read methods. In addition to resolving structural variants and repeat expansions, HiFi WGS captures epigenomic information in parallel, giving researchers a multidimensional view of the genome. This level of detail opens the door to identifying a wider range of genetic variants, many of which are implicated in early-onset and rare diseases that previously went undetected. 'Every child deserves the best possible start to life, and that begins with giving families and clinicians access to comprehensive genomic information from the very beginning,' said Christian Henry, President and Chief Executive Officer of PacBio. 'This collaboration demonstrates how advanced sequencing technologies like HiFi can enable broader insights at birth. It's deeply aligned with our mission at PacBio to make high-quality genomic information accessible where it's needed most, and we're proud to support Chulalongkorn University and Thailand as they lead the way in laying the foundation for a new model of care.' This collaboration positions Thailand as a regional leader in population-scale genomics and reflects Asia Pacific's expanding influence in the global genomics landscape. With an established foundation in public health and translational research, Thailand is uniquely prepared to explore how whole genome sequencing can enhance national healthcare strategies, beginning with newborn screening. By applying PacBio's HiFi long-read sequencing to this early-stage initiative, researchers gain a more comprehensive view of the genome, enabling the detection of variants that are often missed by traditional methods. The ability to capture a wider spectrum of genetic risk at birth sets a new benchmark for the potential of early disease detection, while also contributing to broader goals in carrier screening and public health planning. For Thailand, this project strengthens its role in advancing precision medicine and lays critical groundwork for future data-sharing frameworks and cross-border research collaborations that can inform more equitable and effective genomic healthcare worldwide. About PacBio PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. About Faculty of Medicine, Chulalongkorn University in Thailand Chulalongkorn University is the oldest national university in the Kingdom of Thailand. The university has been active in international research activities and is committed to creating knowledge and innovation to transform Thai society into a creative and sustainable future. As part of the university's mission is to contribute the knowledge gained to the sustainable development of the country and society, the Faculty of Medicine is also actively involved in sharing knowledge with society through collaboration between industry, government, and Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, quality or performance of, the benefits or expected benefits of using, PacBio products or technologies, including in connection with Thailand's efforts to integrate PacBio products into newborn screening; establishing a research model that may uncover the genetic basis of undiagnosed conditions, improve outcomes, ease uncertainty or offer answers earlier, and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results. These risks include, but are not limited to, risks inherent in developing and commercializing new technologies; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with general macroeconomic conditions and geopolitical instability. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption 'Risk Factors.' These forward-looking statements, including PacBio's preliminary unaudited financial information and PacBio's financial guidance, are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available. Contacts (PacBio) Investors: Todd Friedmanir@ Media:pr@ Contacts (Chulalongkorn University) Media:prmdcu@ in to access your portfolio
